

21 August 2009

2009/10 Multi-product Tender

PHARMAC is seeking feedback from Medical Groups, DHB Hospital Pharmacies and other Interested Parties on:

- A proposal to tender certain pharmaceuticals for sole supply; and
- The draft process and terms and conditions for the Invitation to Tender 2009/10.

PHARMAC welcomes all feedback.

ALL RESPONSES ARE DUE BY 5PM, FRIDAY 2 OCTOBER 2009

Feedback should be provided by submitting an email, fax or letter to:

Yvonne Chen
Tender Analyst
PHARMAC
PO Box 10-254
Wellington 6143

Email: yvonne.chen@pharmac.govt.nz

Fax: (04) 460 4995

DDI: (04) 916 7556

All feedback received by the deadline may be considered by the Tender Medical Evaluation Subcommittee of PTAC, and will be considered by the PHARMAC Board (or Chief Executive acting under delegated authority) prior to making a decision on this proposal.

Details of the proposed 2009/10 multi-product tender

In accordance with PHARMAC's objective (to secure, for eligible people in need of pharmaceuticals, the best health outcomes that are reasonably achievable from pharmaceutical treatment and from within the amount of funding provided) PHARMAC is consulting on a proposal to tender, for Sole Subsidised Supply and/or Hospital Supply Status, certain pharmaceuticals.

Attached to this letter (as Schedule One) is a list of pharmaceuticals that we are considering tendering for Sole Subsidised Supply to community pharmacies and/or Hospital Supply Status for supply to DHB Hospital pharmacies. Pharmaceuticals are sorted into therapeutic groups and then listed alphabetically in each group by chemical, form and strength. Each pharmaceutical has a 'C' and/or 'H' next to it to indicate whether it is proposed to be tendered for community and/or hospital supply.

In general, the proposed Tender process would be similar to the 2008/09 Tender. A copy of the draft 2009/10 Invitation to Tender is available on our website: www.pharmac.govt.nz, or by contacting PHARMAC. We are seeking feedback on the approach outlined in the following pages, in particular on:

- The proposed process;
- The proposed timetable;

- The actual or potential clinical implications of awarding Sole Subsidised Supply and/or Hospital Supply Status to the pharmaceuticals listed in Schedule One; and
- For hospital pharmaceuticals, your views on the appropriate Discretionary Variance Limit for each pharmaceutical, in the event you consider a 1% Discretionary Variance Limit to be clinically unacceptable.

Background

Since 1997 PHARMAC has been using the strategy of tendering for the sole supply of pharmaceuticals for a fixed period of time. Tendering has proven to be an effective way to encourage competition among suppliers of pharmaceuticals. It is proposed that, as in the past, the community Tender and hospital Tender processes are run in unison, however the pharmaceutical list for community and hospital pharmacies may be different.

Key Aspects of Awarding a Tender for Community Pharmaceuticals:

- For the community pharmaceuticals the Tender winning brand would be the only subsidised brand for approximately 2½ years. The Sole Subsidised Supply period would conclude on 30 June 2013 for all Tenders awarded from the 2009/10 Invitation to Tender.
- The Sole Subsidised Supply brand would be fully subsidised for the Tender period which means a pharmaceutical that currently carries a manufacturer's surcharge (that is the additional patient charge above that of the patient co-payment), would become fully subsidised if a Tender was awarded.
- No other brand of the pharmaceutical could be listed (or subsidised) in Section B of the Pharmaceutical Schedule during the Tender period.
- Other brands could continue to be marketed, sold and dispensed in New Zealand, however they would not receive a subsidy.

Key Aspects of Awarding a Tender for DHB Hospital Pharmaceuticals:

- For DHB Hospital pharmaceuticals, the Hospital Supply Status brand would be the only brand DHB Hospitals could purchase (excluding any allowance for alternative brands under the agreed Discretionary Variance Limits) for approximately 2½ years. The Hospital Supply Status period would conclude on 30 June 2013 for all Tenders awarded from the 2009/10 Invitation to Tender.
- No other brand of the pharmaceutical would be listed (or purchased) in Section H of the Pharmaceutical Schedule during the Tender period except as allowed under any DV Limits.

Tender Timelines

The Tender process is run annually. This year we are proposing to bring the tender timelines forward by one month; the proposed timelines for the 2009/10 Tender are as follows:

Date	Event
August/September 2009	Consultation with suppliers, medical groups and interested parties on the proposed pharmaceutical list and draft Invitation to Tender.
2 October 2009 (5 pm)	Final date for all consultation to be received.
October 2009	Meeting of the Tender Medical Evaluation Subcommittee of PTAC to consider clinical issues in relation to the proposed Tender list.

Date	Event
October/November 2009	Consultation and Board decisions on Alternative Commercial Proposals to tendering from pharmaceutical suppliers.
Late November 2009	Issuing of the 2009/10 Invitation to Tender.
Late January 2010	Invitation to Tender closes.
From February 2010	Board decisions on the first Tender winners announced.
30 June 2013	End of the sole supply period for all pharmaceuticals where a Tender is awarded from the 2009/10 Tender. Terms after the End Date may apply.

Depending on the feedback received from consultation this year, PHARMAC proposes to bring forward the tender timelines by a further month in the 2010/11 Tender, as this may help to alleviate a number of stock management issues for pharmaceutical suppliers that currently exist during the transition period of a brand change.

Reference Pricing in the Community

Reference pricing, in the community market, is based on the classification of pharmaceuticals into Therapeutic Subgroups. A Therapeutic Subgroup is defined as a set of pharmaceuticals that produce the same or similar therapeutic effect in treating the same or similar condition(s).

The draft list in Schedule One contains pharmaceuticals that belong in an existing Therapeutic Subgroup. In some cases, PHARMAC may be considering tendering more than one pharmaceutical in a Therapeutic Subgroup. Where this is the case it gives rise to a number of scenarios in the community market including:

- 1) It is possible that awarding Sole Subsidised Supply to one pharmaceutical could result in changes to the subsidies for other pharmaceuticals in the same Therapeutic Subgroup; and/or
- 2) Where more than one pharmaceutical in a Therapeutic Subgroup is included on the list, PHARMAC may award Sole Subsidised Supply to each pharmaceutical (and therefore not apply reference pricing in the usual way) or may only award Sole Subsidised Supply to one pharmaceutical and apply reference pricing to the others.

Such scenarios could give rise to new or increased manufacturer surcharges. We ask that you consider and provide feedback on any clinical issues associated with such scenarios.

Contractual obligations for suppliers

A copy of the draft terms and conditions which would form the terms of the contract with successful suppliers in the 2009/10 Tender is available on the PHARMAC website: www.pharmac.govt.nz, or by phoning PHARMAC on 0800 66 00 50.

Unresolved Tender Bids

PHARMAC would review any unresolved Tender Bids from the Invitation to Tender dated 21 December 2007 (2007/08 Tender) and the Invitation to Tender dated 23 December 2008 (2008/09 Tender) prior to issuing the 2009/10 Invitation to Tender.

Should any unresolved Tender Bids be declined, PHARMAC would consider re-tendering those pharmaceuticals when the Invitation to Tender is issued in November 2009. Currently unresolved Tender Bids have not been included in the draft pharmaceutical list set out in Schedule One.

PHARMAC is currently seeking comments from suppliers about keeping any unresolved Tender Bid(s) open for acceptance.

Distribution of Consultation Documents

Please note that this consultation letter has been widely distributed, however should you consider that a particular person, group or agency should receive this letter and/or future Tender documents please feel free to contact PHARMAC (note, all Tender documents and consultations are also available from our website). We also invite any person or group to contact PHARMAC should you wish to meet to discuss the proposals contained in this consultation letter.

Schedule One: Possible pharmaceuticals for tender for sole supply

Order of pharmaceuticals in this Schedule

The pharmaceuticals have been listed in therapeutic groups according to the therapeutic group classification system used in the Pharmaceutical Schedule. Below is a list of the groups, and the corresponding page numbers for your ease of reference. Please note that pharmaceuticals with indications that may apply to multiple therapeutic groups will only appear in one.

Therapeutic Group	Page Numbers
Alimentary Tract and Metabolism	7 – 9
Blood and Blood Forming Organs	9 – 10
Cardiovascular System	10 – 11
Dermatologicals	11 – 13
Extemporaneously Compounded Preparations	13
Genito-Urinary System	13
Hormone Preparations – Systemic excluding contraceptives	13 – 14
Infections – Agents for Systemic Use	14 – 15
Musculoskeletal System	15 – 16
Nervous System	16 – 22
Oncology and Immunosuppressants	22 – 26
Respiratory System and Allergies	26
Sensory Organ	26
Various	26

Information provided for each pharmaceutical

For each pharmaceutical (as defined by chemical name, form and strength) we have provided the following information:

- the current ex-manufacturer subsidy per unit of measure as at 1 August 2009;
- number of subsidised or partially subsidised units sold in the community in the year ending 30 June 2009. We note that these figures have not yet been finalised; however finalised data would be captured in the final Invitation to Tender;
- estimated annual community market value at current subsidies; and
- comments specifically relating to the Tender of the line item and/or its current listing on the Pharmaceutical Schedule.

The figures for the number of units subsidised in community pharmacies are approximate and are based on the year ending June 2009. These figures are indicative only and sales are not guaranteed. PHARMAC makes no representation as to the level of sales or likely sales of any tender item. There are no figures available for hospital pharmaceuticals.

We have estimated market value by multiplying the volume of units subsidised in the year ending 30 June 2009 by the relevant listed unit subsidy as at 1 August 2009.

Explanation of terms, symbols and abbreviations

Most terms and abbreviations used are self explanatory: “tab” means tablet, “cap” means capsule, “liq” means liquid, “inj” means injection, “suppos” means suppository, “grans” mean granules and “OP” means original pack to be dispensed.

The following table explains the symbols used in the draft pharmaceutical list:

Symbol	Explanation
Underline	Pharmaceutical line items where a sole supply contract is in force are underlined. The price and subsidy for these pharmaceuticals are fixed until 30 June 2010 unless otherwise stated in the Comments column and a listing of a new brand could only occur until after that date.
C	To be tendered for Sole Subsidised Supply (community pharmaceuticals).
H	To be tendered for Hospital Supply Status (DHB Hospital pharmaceuticals).
PCT	A reference in the Invitation to Tender to allow Pharmaceuticals Cancer Treatments to be listed in Section B of the Pharmaceutical Schedule as part of PHARMAC’s Pharmaceutical Cancer Treatments project.
+	PHARMAC has been advised of the existence of a process patent.
*	There is no fully funded product available for this line item (in relation to community supply).

SCHEDULE ONE: PHARMACEUTICALS TO BE TENDERED (DRAFT)

Chemical Name

Line Item

Units

Cost

Unit Subsidy

DV Limit

Comments

Alimentary Tract and Metabolism

Ascorbic Acid

Eye drops 10%					H	1%	
Inj 500 mg per 5 ml					H	1%	
Tab 50 mg					C H	1%	Not currently listed on the Pharmaceutical Schedule
Tab 100 mg	1,329,567	\$45,870	\$0.0345		C H	1%	
Tab 250 mg					C H	1%	Not currently listed on the Pharmaceutical Schedule

Bisacodyl

Tab 5 mg	1,551,489	\$39,485	\$0.0255		C H	1%	
----------	-----------	----------	----------	--	-----	----	--

Cholecalciferol

Tab 1.25 mg (50,000 iu)	1,176,907	\$1,015,082	\$0.8625		C H	1%	
-------------------------	-----------	-------------	----------	--	-----	----	--

Esomeprazole

Inj 40 mg					C H	1%	Not currently listed on the Pharmaceutical Schedule
Tab 20 mg					C H	1%	Not currently listed on the Pharmaceutical Schedule
Tab 40 mg					C H	1%	Not currently listed on the Pharmaceutical Schedule

Famotidine

Tab 20 mg	709,966	\$23,003	\$0.0324		C H	1%	
Tab 40 mg	621,078	\$28,197	\$0.0454		C H	1%	

Ferrous Salts

Oral liq	3,817,372	\$78,638	\$0.0206		C H	1%	
Tab (short-acting)					C H	1%	Any iron salt and additives would be considered. Dose range of 60 - 105 mg elemental iron per tablet required
Tab (long-acting)					C H	1%	Any iron salt and additives would be considered. Dose range of 60 - 105 mg elemental iron per tablet required

Fluocortolone Caproate with Fluocortolone Pivalate and Cinchocaine

<u>Oint 950 mcg, with fluocortolone pivalate 920 mcg, and cinchocaine hydrochloride 5 mg per g</u>	2,353,042	\$498,061	\$0.2117		C H	1%	All corticosteroids ointments in the antihemorrhoidals group are considered as one Tender Item
<u>Suppos 630 mcg, with fluocortolone pivalate 610 mcg, and cinchocaine hydrochloride 1 mg</u>	730,228	\$161,867	\$0.2217		C H	1%	All corticosteroids suppositories in the antihemorrhoidals group are considered as one Tender Item

Glimepiride

Tab 1 mg					C H	1%	Not currently listed on the Pharmaceutical Schedule
Tab 2 mg					C H	1%	Not currently listed on the Pharmaceutical Schedule

SCHEDULE ONE: PHARMACEUTICALS TO BE TENDERED (DRAFT)

Chemical Name							
Line Item	Units	Cost	Unit Subsidy		DV Limit	Comments	
Glimepiride							
Tab 3 mg				C H	1%	Not currently listed on the Pharmaceutical Schedule	
Tab 4 mg				C H	1%	Not currently listed on the Pharmaceutical Schedule	
Glycerol							
Suppos 3 g or less	56,472	\$14,683	\$0.2600	C H	1%		
Suppos greater than 3 g	263,122	\$65,781	\$0.2500	C H	1%		
Hydrocortisone with Cinchocaine							
Oint 5 mg with cinchocaine hydrochloride 5 mg per g				C H	1%	Not currently listed in the Pharmaceutical Schedule. All corticosteroids ointments in the antihemorrhoidals group are considered as one Tender Item	
Suppos 5 mg with cinchocaine hydrochloride 5 mg per g				C H	1%	Not currently listed in the Pharmaceutical Schedule. All corticosteroids suppositories in the antihemorrhoidals group are considered as one Tender Item	
Hydrocortisone with Lignocaine, Aluminium and Zinc							
Oint 0.25% with lignocaine hydrochloride 5% aluminium subacet 3.5% and zinc oxide 18%				C H	1%	Not currently listed in the Pharmaceutical Schedule. All corticosteroids ointments in the antihemorrhoidals group are considered as one Tender Item	
Suppos 0.25% with lignocaine hydrochloride 5% aluminium subacet 3.5% and zinc oxide 18%				C H	1%	Not currently listed in the Pharmaceutical Schedule. All corticosteroids suppositories in the antihemorrhoidals group are considered as one Tender Item	
Lactulose							
Oral liq 10 g per 15 ml	182,005,412	\$1,210,336	\$0.0067	C H	1%		
Loperamide Hydrochloride							
Tab 2 mg	6,069,760	\$174,506	\$0.0288	C		Capsule form would be considered	
Mesalazine							
Tab 400 mg	2,197,126	\$1,087,577	\$0.4950	C H	1%		
Miconazole							
Oral gel 20 mg per g	660,769	\$143,717	\$0.2175	C H	1%		
Nizatidine							
Cap 150 mg				C	1%	Not currently listed on the Pharmaceutical Schedule	
Cap 300 mg				C H	1%	Not currently listed on the Pharmaceutical Schedule	
Pantoprazole							
Inj 40 mg			\$8.7500	C H	1%		
Tab 20 mg	4,351,274	\$348,102	\$0.0800	C H	1%		

SCHEDULE ONE: PHARMACEUTICALS TO BE TENDERED (DRAFT)

Chemical Name	Units	Cost	Unit Subsidy	DV Limit	Comments
Line Item					
Pantoprazole					
Tab 40 mg	7,307,110	\$876,853	\$0.1200	C H	1%
Pyridoxine Hydrochloride					
Tab 25 mg	643,577	\$21,882	\$0.0340	C H	1%
Rabeprazole					
Tab 10 mg				C H	1% Not currently listed on the Pharmaceutical Schedule
Tab 20 mg			\$0.0000	C H	1% Not currently listed on the Pharmaceutical Schedule
Sodium Citrate with Sodium Lauryl Sulphoacetate					
Enema 90 mg with sodium lauryl sulphoacetate 9 mg per ml, 5 ml	339,630	\$206,597	\$0.6083	C H	1%
Vitamin B Complex (BPC, strong)					
Tab	2,369,926	\$57,352	\$0.0242	C	
Vitamins (BPC cap strength)					
Tab	24,790,242	\$366,896	\$0.0148	C	
Blood and Blood Forming Organs					
Aspirin					
Tab 100 mg	102,957,010	\$1,750,269	\$0.0170	C	
Atorvastatin					
Tab 10 mg	4,827,918	\$648,389	\$0.1343	* + C	A Special Authority for the Manufacturers Price currently exists. The total cost, accounting for patients with Special Authority, was \$2,878,089 for the year ended 30 June 2009
Tab 20 mg	6,791,393	\$1,329,076	\$0.1957	* + C	A Special Authority for the Manufacturers Price currently exists. The total cost, accounting for patients with Special Authority, was \$5,953,386 for the year ended 30 June 2009
Tab 40 mg	8,504,025	\$2,307,142	\$0.2713	* + C	A Special Authority for the Manufacturers Price currently exists. The total cost, accounting for patients with Special Authority, was \$10,440,546 for the year ended 30 June 2009
Tab 80 mg			\$0.5427	* + C	This was recently listed on the Pharmaceutical Schedule. A Special Authority for the Manufacturers Price currently exists
Clopidogrel					
Tab 75 mg	1,820,845	\$2,276,056	\$1.2500	C H	1%
Compound Electrolytes					
<u>Powder for soln for oral use</u>	791,686	\$226,422	\$0.2860	C	

SCHEDULE ONE: PHARMACEUTICALS TO BE TENDERED (DRAFT)

Chemical Name

Line Item	Units	Cost	Unit Subsidy		DV Limit	Comments	
Dextrose with Electrolytes							
<u>Soln with electrolytes</u>	90,789,984	\$604,661	\$0.0067		C	Sole supply would only be awarded to a range of flavours	
Gemfibrozil							
Tab 300 mg					C H	1%	Not currently listed on the Pharmaceutical Schedule. Capsule form would be considered
Tab 600 mg					C H	1%	Not currently listed on the Pharmaceutical Schedule. Capsule form would be considered
Sodium Chloride							
Inj 0.9%, 5 ml	133,175	\$30,630	\$0.2300		C H	1%	
Inj 0.9%, 10 ml	543,388	\$124,979	\$0.2300		C H	1%	
Inj 0.9%, 20 ml	102,212	\$40,169	\$0.3930		C H	1%	
Inj 23.4%, 20 ml	3,735	\$19,796	\$5.3000		C H	1%	
Sodium Fluorescein							
Inj 100 mg per ml					H	1%	

Cardiovascular System

Acebutolol							
Cap 100 mg	60,820	\$5,778	\$0.0950		C H	1%	
Cap 200 mg	130,884	\$20,863	\$0.1594		C H	1%	
Tab 400 mg					C H	1%	Not currently listed on the Pharmaceutical Schedule
Amiodarone Hydrochloride							
Inj 50 mg per ml, 3 ml	4,793	\$29,161	\$6.0840		C H	1%	
Bisoprolol fumarate							
Tab 2.5 mg					C		Not currently listed on the Pharmaceutical Schedule. Tender Agreement may be subject to a Special Authority
Tab 5 mg					C		Not currently listed on the Pharmaceutical Schedule. Tender Agreement may be subject to a Special Authority
Tab 10 mg					C		Not currently listed on the Pharmaceutical Schedule. Tender Agreement may be subject to a Special Authority
Bumetanide							
Tab 1 mg	836,929	\$136,922	\$0.1636		C H	1%	
Captopril							
Oral liq 5 mg per ml	85,273	\$45,814	\$0.5373		C H	1%	
<u>Tab 12.5 mg</u>	505,495	\$10,514	\$0.0208		C H	1%	
<u>Tab 25 mg</u>	830,687	\$22,262	\$0.0268		C H	1%	

SCHEDULE ONE: PHARMACEUTICALS TO BE TENDERED (DRAFT)

Chemical Name	Units	Cost	Unit Subsidy	DV Limit	Comments
Captopril					
<u>Tab 50 mg</u>	637,696	\$24,232	\$0.0380	C H	1%
Cilazapril					
Tab 0.5 mg	14,646,190	\$1,074,054	\$0.0733	C	
Tab 2.5 mg	17,316,642	\$2,534,002	\$0.1463	C	
Tab 5 mg	16,520,567	\$3,546,415	\$0.2147	C	
Cilazapril with Hydrochlorothiazide					
Tab 5 mg with Hydrochlorothiazide 12.5 mg	17,897,458	\$4,026,928	\$0.2250	C	
Dobutamine					
Inj 12.5 mg per ml, 20 ml				H	1%
Doxazosin Mesylate					
<u>Tab 2 mg</u>	9,601,118	\$438,771	\$0.0457	C H	1%
<u>Tab 4 mg</u>	8,384,024	\$507,401	\$0.0605	C H	1%
Furosemide					
Inj 10 mg per ml, 2 ml	19,591	\$11,559	\$0.5900	C H	1%
Inj 20 mg per ml, 2 ml				C H	1% Not currently listed on the Pharmaceutical Schedule
Glycerol Trinitrate					
Inj 5 mg per ml, 1 ml				H	1%
Inj 5 mg per ml, 10 ml				H	1%
Hydralazine					
Inj 20 mg per ml, 1 ml	52	\$269	\$5.1800	C H	1%
Prazosin Hydrochloride					
<u>Tab 1 mg</u>	401,233	\$22,188	\$0.0553	C H	1%
<u>Tab 2 mg</u>	407,528	\$28,527	\$0.0700	C H	1%
<u>Tab 5 mg</u>	267,577	\$31,307	\$0.1170	C H	1%
Spironolactone					
Tab 25 mg	5,328,826	\$452,950	\$0.0850	C H	1%
Tab 100 mg	1,295,640	\$281,154	\$0.2170	C H	1%
Terazosin Hydrochloride					
Tab 1 mg			\$0.0893	C	This was recently listed on the Pharmaceutical Schedule
<u>Tab 2 mg</u>	3,816,567	\$177,852	\$0.0466	C	
<u>Tab 5 mg</u>	2,895,729	\$167,952	\$0.0580	C	
Dermatologicals					
Calcipotriol					
Crn 50 mcg per g (pack size 30 g or less)	1,419,618	\$821,817	\$0.5789	C H	1% Volume is aggregated for all pack sizes of calcipotriol cream

SCHEDULE ONE: PHARMACEUTICALS TO BE TENDERED (DRAFT)

Chemical Name							
Line Item	Units	Cost	Unit Subsidy		DV Limit	Comments	
Calcipotriol							
Crn 50 mcg per g (pack size greater than 30 g)	1,419,618	\$821,817	\$0.5789	C H	1%	Volume is aggregated for all pack sizes of calcipotriol cream	
Oint 50 mcg per g (pack size 30 g or less)	1,507,289	\$1,043,044	\$0.6920	C H	1%	Volume is aggregated for all pack sizes of calcipotriol ointment	
Oint 50 mcg per g (pack size greater than 30 g)	1,507,289	\$1,043,044	\$0.6920	C H	1%	Volume is aggregated for all pack sizes of calcipotriol ointment	
Soln 50 mcg per ml (pack size 30 ml or less)	313,503	\$217,153	\$0.6927	C H	1%	Volume is aggregated for all pack sizes of calcipotriol solution	
Soln 50 mcg per ml (pack size greater than 30 ml)	313,503	\$217,153	\$0.6927	C H	1%	Volume is aggregated for all pack sizes of calcipotriol solution	
Cetomacrogol							
<u>Crn BP</u>	12,146,581	\$85,026	\$0.0070	C			
Coal Tar							
Soln BP			\$0.0730	C		There are two different subsidies, unit subsidy reflects the subsidy of the fully funded product. Market information unavailable	
Fusidic Acid							
<u>Crn 2 %</u>	1,466,886	\$386,280	\$0.2633	C H	1%		
<u>Oint 2 %</u>	1,002,501	\$263,992	\$0.2633	C H	1%		
Hydrocortisone Butyrate							
<u>Scalp lotn 0.1%</u>	3,642,476	\$273,914	\$0.0752	C H	1%		
Hydrocortisone with Natamycin and Neomycin							
Crn 1% with natamycin 1% and neomycin sulphate 0.5%	1,793,319	\$526,040	\$0.2933	C			
Oint 1% with natamycin 1% and neomycin sulphate 0.5%	817,977	\$239,940	\$0.2933	C			
Magnesium Sulphate							
Paste (pack size 100 g or less)	245,281	\$9,137	\$0.0373	C H	1%		
Malathion							
<u>Liq 0.5%</u>	9,322,516	\$232,597	\$0.0250	C			
<u>Shampoo 1%</u>	564,454	\$53,247	\$0.0943	C			
Menthol							
Crystals			\$0.2960	C		Market information unavailable	
Salicylic Acid							
Powder			\$0.0755	C		Market information unavailable	
Sulphur							
Precipitated			\$0.0650	C		Market information unavailable	

SCHEDULE ONE: PHARMACEUTICALS TO BE TENDERED (DRAFT)

Chemical Name

Line Item	Units	Cost	Unit Subsidy	DV Limit	Comments
Wool Fat with Mineral Oil					
Lotn hydrous 3% with mineral oil	10,719,597	\$60,030	\$0.0056 *	C	
Zinc					
Crm BP	220,121	\$2,884	\$0.0131 *	C	

Extemporaneously Compounded Preparations & Galenicals

Glycerol

Liq BP			\$0.0124	C H	1%	Market information unavailable
--------	--	--	----------	-----	----	--------------------------------

Methyl Hydroxybenzoate

Powder			\$0.4000	C		Market information unavailable
--------	--	--	----------	---	--	--------------------------------

Methylcellulose

Powder			\$0.1400	C		Market information unavailable
--------	--	--	----------	---	--	--------------------------------

Propylene Glycol

Liq			\$0.0354	C		Market information unavailable
-----	--	--	----------	---	--	--------------------------------

Sodium Bicarbonate

Powder BP			\$0.0196	C H	1%	Market information unavailable
-----------	--	--	----------	-----	----	--------------------------------

Genito-Urinary System

Clotrimazole

Pessaries 100 mg with applicator(s)				C		Not currently listed on the Pharmaceutical Schedule
-------------------------------------	--	--	--	---	--	---

Pessaries 500 mg with applicator				C		Not currently listed on the Pharmaceutical Schedule
----------------------------------	--	--	--	---	--	---

<u>Vaginal crm 1% with applicators</u>	1,914,684	\$79,323	\$0.0414	C H	1%	
--	-----------	----------	----------	-----	----	--

<u>Vaginal crm 2% with applicators</u>	1,086,351	\$149,373	\$0.1375	C H	1%	
--	-----------	-----------	----------	-----	----	--

Ergometrine Maleate

Inj 500 mcg per ml, 1 ml	1,023	\$2,373	\$2.3200	C H	1%	
--------------------------	-------	---------	----------	-----	----	--

Levonorgestrel

Tab 30 mcg	836,896	\$65,955	\$0.0788	C		
------------	---------	----------	----------	---	--	--

Tab 750 mcg - 1.5 mg	56,343	\$704,288	\$12.5000	C		Bids would be accepted for a tablet within this strength range
----------------------	--------	-----------	-----------	---	--	--

Oxybutynin

<u>Oral liq 5 mg per 5 ml</u>	612,575	\$65,272	\$0.1066	C H	1%	
-------------------------------	---------	----------	----------	-----	----	--

<u>Tab 5 mg</u>	5,876,883	\$526,451	\$0.0896	C H	1%	
-----------------	-----------	-----------	----------	-----	----	--

Sodium Citro-Tartrate

<u>Grans effervescent 4 g sachets</u>	1,372,285	\$134,778	\$0.0982	C		
---------------------------------------	-----------	-----------	----------	---	--	--

Hormone Preparations - Systemic Excluding Contraceptive Hormones

SCHEDULE ONE: PHARMACEUTICALS TO BE TENDERED (DRAFT)

Chemical Name

Line Item	Units	Cost	Unit Subsidy	DV Limit	Comments
Dexamethasone Sodium Phosphate					
Inj 4 mg per ml, 1 ml	31,713	\$136,366	\$4.3000	C H	1%
Inj 4 mg per ml, 2 ml	76,573	\$474,753	\$6.2000	C H	1%
Hydrocortisone					
Inj 50 mg per ml, 2 ml	6,999	\$26,036	\$3.7200	C H	1%
Medroxyprogesterone Acetate					
<u>Tab 2.5 mg</u>	221,643	\$15,293	\$0.0690	C H	1%
<u>Tab 5 mg</u>	519,805	\$71,473	\$0.1375	C H	1%
<u>Tab 10 mg</u>	864,393	\$218,115	\$0.2523	C H	1%
<u>Tab 100 mg</u>	44,252	\$46,137	\$1.0426	C H	1%
<u>Tab 200 mg</u>	1,192	\$3,102	\$2.6020	C H	1%
Testosterone					
Transdermal patch 2.5 mg per day	105,858	\$141,140	\$1.3333	C H	1%

Infections - Agents for Systemic Use

Abacavir Sulphate

Oral liq 20 mg per ml	42,936	\$17,890	\$0.4167	C H	1%
Tab 300 mg	35,393	\$270,167	\$7.6333	C H	1%

Abacavir sulphate with lamivudine

Tab 600 mg with lamivudine 300 mg	60,587	\$1,272,327	\$21.0000	C H	1%
-----------------------------------	--------	-------------	-----------	-----	----

Abacavir Sulphate with Lamivudine and Zidovudine

Tab 300 mg with lamivudine 150 mg, and zidovudine 300 mg				C	Not currently listed on the Pharmaceutical Schedule
--	--	--	--	---	---

Amoxicillin

<u>Cap 250 mg</u>	1,728,107	\$59,793	\$0.0346	C H	1%
<u>Cap 500 mg</u>	10,097,812	\$550,331	\$0.0545	C H	1%

Cefaclor Monohydrate

<u>Cap 250 mg</u>	3,894,014	\$1,125,370	\$0.2890	C H	1%
<u>Grans for oral liq 125 mg per 5 ml</u>	10,276,124	\$402,824	\$0.0392	C H	1%

Ciprofloxacin

Inj 2 mg per ml, 100 ml				H	1%
-------------------------	--	--	--	---	----

Clarithromycin

<u>Tab 250 mg</u>	86,986	\$48,153	\$0.5536	C H	1%
-------------------	--------	----------	----------	-----	----

Clindamycin

Inj phosphate 150 mg per ml, 4 ml	1,141	\$22,192	\$19.4500	C H	1%
-----------------------------------	-------	----------	-----------	-----	----

Colistin Sulphomethate

<u>Inj 150 mg</u>	7,452	\$484,380	\$65.0000	C H	1%
-------------------	-------	-----------	-----------	-----	----

Emtricitabine

Cap 200 mg	124,667	\$1,276,590	\$10.2400	C H	1%
------------	---------	-------------	-----------	-----	----

SCHEDULE ONE: PHARMACEUTICALS TO BE TENDERED (DRAFT)

Chemical Name

Line Item	Units	Cost	Unit Subsidy		DV Limit	Comments
Gentamicin Sulphate						
Inj 10 mg per ml, 1 ml			\$1.7120	C H	1%	Market information unavailable
Isoniazid						
Tab 100 mg	271,862	\$55,732	\$0.2050	C		
Itraconazole						
<u>Cap 100 mg</u>	581,374	\$918,571	\$1.5800	C H	1%	
Lamivudine						
Oral liq 5 mg per ml	6,220	\$2,333	\$0.3750	C		
Oral liq 10 mg per ml	36,198	\$15,083	\$0.4167	C		
Tab 100 mg	327,610	\$1,673,151	\$5.1071	C		
Tab 150 mg	32,249	\$165,115	\$5.1200	C		
Lopinavir with ritonavir						
Oral liq 80 mg with ritonavir 20 mg per ml	17,838	\$43,703	\$2.4500	+ C H	1%	Tender agreement may be subject to a Special Authority restriction
Tab 200 mg with ritonavir 50 mg	217,934	\$1,334,846	\$6.1250	+ C H	1%	Tender agreement may be subject to a Special Authority restriction
Metronidazole						
Tab 200 mg	288,833	\$27,439	\$0.0950	C		
Tab 400 mg	1,103,006	\$193,026	\$0.1750	C		
Nystatin						
<u>Cap 500,000 u</u>	230,477	\$53,655	\$0.2328	C H	1%	
<u>Tab 500,000 u</u>	76,029	\$14,598	\$0.1920	C H	1%	
Phenoxymethylpenicillin (Penicillin V)						
<u>Cap 250 mg</u>	555,005	\$47,619	\$0.0858	C H	1%	
<u>Cap 500 mg</u>	2,342,365	\$381,805	\$0.1630	C H	1%	
<u>Grans for oral liq benzathine 125 mg per 5 ml</u>	2,061,408	\$34,632	\$0.0168	C H	1%	
<u>Grans for oral liq benzathine 250 mg per 5 ml</u>	4,896,391	\$89,114	\$0.0182	C H	1%	
Piperacillin Sodium with Tazobactam Sodium						
Inj 4 g with tazobactam sodium 500 mg				H	1%	
Rifabutin						
<u>Cap 150 mg</u>	10,269	\$72,975	\$7.1063	C H	1%	
Zidovudine (AZT)						
Cap 100 mg	47,957	\$139,075	\$2.9000	+ C H	1%	
Oral liq 10 mg per ml	60,246	\$17,471	\$0.2900	+ C H	1%	

Musculoskeletal System

Colchicine

<u>Tab 500 mcg - 600 mcg</u>	3,618,128	\$347,340	\$0.0960	C H	1%	
------------------------------	-----------	-----------	----------	-----	----	--

SCHEDULE ONE: PHARMACEUTICALS TO BE TENDERED (DRAFT)

Chemical Name

Line Item	Units	Cost	Unit Subsidy	DV Limit	Comments
Ibuprofen					
<u>Oral liq 100 mg per 5 ml</u>	27,842,543	\$485,852	\$0.0175	C H	1%
Indomethacin					
Cap 25 mg	291,147	\$17,178	\$0.0590	C H	1%
Cap 50 mg	782,475	\$54,382	\$0.0695	C H	1%
Cap long-acting 75 mg	589,424	\$78,393	\$0.1330	C H	1%
Suppos 100 mg	39,921	\$19,295	\$0.4833	C H	1%
Naproxen					
Tab long-acting 750 mg	893,953	\$178,791	\$0.2000	C H	1%
Tab long-acting 1,000 mg	813,534	\$189,825	\$0.2333	C H	1%
Naproxen Sodium					
<u>Tab 275 mg</u>	1,890,518	\$94,526	\$0.0500	C H	1%
Tab 550 mg	4,289,670	\$549,078	\$0.1280	C H	1%
Neostigmine					
<u>Inj 2.5 mg per ml, 1 ml</u>	27,169	\$11,031	\$0.4060	C H	1%
Orphenadrine Citrate					
Tab 100 mg	1,436,969	\$266,414	\$0.1854	C H	1%
Piroxicam					
Tab dispersible 10 mg	41,511	\$2,698	\$0.0650	C H	1%
Tab dispersible 20 mg	389,484	\$21,422	\$0.0550	C H	1%
Risedronate sodium					
Tab 5 mg				C H	1% Not currently listed on the Pharmaceutical Schedule. Tender agreement may be subject to a Special Authority restriction
Tab 30 mg				C H	1% Not currently listed on the Pharmaceutical Schedule. Tender agreement may be subject to a Special Authority restriction
Tab 35 mg				C H	1% Not currently listed on the Pharmaceutical Schedule. Tender agreement may be subject to a Special Authority restriction
Tab 150 mg				C H	1% Not currently listed on the Pharmaceutical Schedule. Tender agreement may be subject to a Special Authority restriction
Tenoxicam					
Tab 20 mg	1,763,099	\$418,736	\$0.2375	C H	1%

Nervous System

Alprazolam

<u>Tab 250 mcg</u>	327,241	\$21,271	\$0.0650	C	
<u>Tab 500 mcg</u>	282,290	\$24,277	\$0.0860	C	

SCHEDULE ONE: PHARMACEUTICALS TO BE TENDERED (DRAFT)

Chemical Name						
Line Item	Units	Cost	Unit Subsidy		DV Limit	Comments
Alprazolam						
<u>Tab 1 mg</u>	84,739	\$13,304	\$0.1570	C		
Apomorphine Hydrochloride						
Inj 10 mg per ml	2,157	\$21,756	\$10.0860	C H	1%	
Aspirin						
<u>Tab dispersible or soluble 300 mg</u>	3,077,961	\$66,176	\$0.0215	C		
Bupivacaine Hydrochloride						
<u>Inf 0.125%, 100 ml theatre pack</u>				H	1%	
<u>Inf 0.125%, 200 ml theatre pack</u>				H	1%	
<u>Inf 0.25%, 100 ml theatre pack</u>				H	1%	
<u>Inj 0.5%, 8% glucose, 4 ml</u>	503	\$2,465	\$4.9000	C H	1%	
Caffeine Citrate						
Inj 10 mg per ml, 2.5 ml				H	1%	
Oral liq 10 mg per ml				H	1%	
Codeine Phosphate						
<u>Tab 15 mg</u>	4,033,866	\$221,863	\$0.0550	C H	1%	
<u>Tab 30 mg</u>	18,209,124	\$1,547,776	\$0.0850	C H	1%	
<u>Tab 60 mg</u>	1,785,587	\$330,334	\$0.1850	C H	1%	
Dexamphetamine Sulphate						
Tab 5 mg	636,761	\$108,249	\$0.1700	C H	1%	
Domperidone						
Tab 10 mg	6,579,837	\$256,614	\$0.0390	C		A Special Authority for full subsidy currently exists. The Special Authority would be removed should a tender be awarded
Ephedrine Sulphate						
Inj 30 mg per ml, 1 ml				H	1%	
Ergotamine Tartrate with Caffeine						
Tab 1 mg with caffeine 100 mg	423,371	\$131,245	\$0.3100	C H	1%	
Escitalopram						
Tab 10 mg				C H	1%	Not currently listed on the Pharmaceutical Schedule
Tab 20 mg				C H	1%	Not currently listed on the Pharmaceutical Schedule
Fluoxetine Hydrochloride						
<u>Cap 20 mg</u>	21,564,650	\$1,051,876	\$0.0488	C H	1%	
<u>Tab dispersible 20 mg, scored</u>	854,866	\$156,725	\$0.1833	C H	1%	
Haloperidol						
Inj 5 mg per ml, 1 ml	39,565	\$67,419	\$1.7040	C H	1%	
<u>Oral liq 2 mg per ml</u>	65,301	\$11,793	\$0.1806	C H	1%	
<u>Tab 500 mcg</u>	1,232,826	\$60,778	\$0.0493	C H	1%	

SCHEDULE ONE: PHARMACEUTICALS TO BE TENDERED (DRAFT)

Chemical Name							
Line Item	Units	Cost	Unit Subsidy		DV Limit	Comments	
Haloperidol							
<u>Tab 1.5 mg</u>	258,263	\$19,241	\$0.0745	C H	1%		
<u>Tab 5 mg</u>	262,642	\$61,695	\$0.2349	C H	1%		
Imipramine Hydrochloride							
Tab 10 mg	496,156	\$54,379	\$0.1096	C H	1%		
Tab 25 mg	1,579,879	\$278,059	\$0.1760	C H	1%		
Ketamine Hydrochloride							
Inj 10 mg per ml				C H	1%		Not currently listed in the Pharmaceutical Schedule. Tender agreement may be subject to a Special Authority restriction
Inj 50 mg per ml				C H	1%		Not currently listed on the Pharmaceutical Schedule. Tender agreement may be subject to a Special Authority restriction
Inj 100 mg per ml				C H	1%		Not currently listed on the Pharmaceutical Schedule. Tender agreement may be subject to a Special Authority restriction
Levodopa with Benserazide							
Cap 50 mg with benserazide 12.5 mg	1,036,487	\$82,919	\$0.0800	C H	1%		
Cap 100 mg with benserazide 25 mg	1,186,884	\$148,361	\$0.1250	C H	1%		
Cap 200 mg with benserazide 50 mg	176,281	\$44,070	\$0.2500	C H	1%		
Cap long-acting 100 mg with benserazide 25 mg	567,392	\$96,457	\$0.1700	C H	1%		
Tab dispersible 50 mg with benserazide 12.5 mg	477,398	\$47,740	\$0.1000	C H	1%		
Lignocaine							
Viscous solution 2%				C H	1%		Not currently listed on the Pharmaceutical Schedule
Lignocaine Hydrochloride							
<u>Inj 0.5%, 5 ml</u>	11,967	\$10,555	\$0.8820	C H	1%		
<u>Pump spray 10%, 50 ml CFC-free</u>				H	1%		
<u>Inj 1%, 5 ml</u>	37,078	\$31,146	\$0.8400	C			
<u>Inj 1%, 20 ml</u>	1,783	\$8,380	\$4.7000	C			
Lignocaine Hydrochloride with Adrenaline							
<u>Inj 1% with 1:100,000 of adrenaline, 5 ml</u>				H	1%		
<u>Inj 1% with 1:200,000 of adrenaline, 20 ml</u>				H	1%		
<u>Inj 2% with 1:200,000 of adrenaline, 20 ml</u>				H	1%		
Lignocaine with Prilocaine Hydrochloride							
Crn 2.5% with prilocaine hydrochloride 2.5% 5 g	577	\$4,731	\$8.2000	C H	1%		
Crn 2.5% with prilocaine hydrochloride 2.5% 30 g	1,335	\$1,825	\$1.3667	C H	1%		
Lithium carbonate							
Tab long-acting 400 mg	1,228,213	\$197,128	\$0.1605	C			

SCHEDULE ONE: PHARMACEUTICALS TO BE TENDERED (DRAFT)

Chemical Name							
Line Item	Units	Cost	Unit Subsidy		DV Limit	Comments	
Lorazepam							
Tab 1 mg	4,504,048	\$113,142	\$0.0251	C H	1%		
Tab 2.5 mg	256,352	\$10,562	\$0.0412	C H	1%		
Methadone Hydrochloride							
Inj 10 mg per ml, 1 ml	35,728	\$217,941	\$6.1000	C H	1%		
<u>Tab 5 mg</u>	1,975,773	\$414,912	\$0.2100	C H	1%		
Metoclopramide Hydrochloride							
Oral liq 5 mg per 5 ml			\$0.0000	C H	1%		Not currently listed on the Pharmaceutical Schedule
Morphine Sulphate							
Cap long-acting 10 mg	2,852,145	\$513,386	\$0.1800	C H	1%		
Cap long-acting 30 mg	1,052,319	\$277,812	\$0.2640	C H	1%		
Cap long-acting 60 mg	408,428	\$294,068	\$0.7200	C H	1%		
Cap long-acting 100 mg	304,539	\$239,063	\$0.7850	C H	1%		
Cap long-acting 200 mg	39,285	\$66,785	\$1.7000	C H	1%		
Inj 5 mg per ml, 1 ml	25,813	\$26,691	\$1.0340	C H	1%		
Inj 15 mg per ml, 1 ml	11,355	\$10,674	\$0.9400	C H	1%		
Tab long-acting 10 mg	728,273	\$131,089	\$0.1800	C H	1%		
Tab long-acting 30 mg	356,403	\$128,305	\$0.3600	C H	1%		
Tab long-acting 60 mg	175,275	\$126,198	\$0.7200	C H	1%		
Tab long-acting 100 mg	244,268	\$207,628	\$0.8500	C H	1%		
Tab long-acting 200 mg				C H	1%		Not currently listed on the Pharmaceutical Schedule
Morphine Tartrate							
Inj 80 mg per ml, 1.5 ml	26,690	\$107,828	\$4.0400	C H	1%		
Inj 80 mg per ml, 5 ml	2,560	\$34,493	\$13.4740	C H	1%		
Naltrexone hydrochloride							
<u>Tab 50 mg</u>	84,773	\$508,638	\$6.0000	C H	1%		
Olanzapine							
Oradisensible 5 mg				+ H	5%		
Orodispersible 10 mg				+ H	5%		
Tab 2.5 mg				+ H	5%		
Tab 5 mg				+ H	5%		
Tab 10 mg				+ H	5%		
Ondansetron							
<u>Tab 4 mg</u>	30,087	\$51,689	\$1.7180	C H	1%		
<u>Tab 8 mg</u>	112,932	\$191,363	\$1.6945	C H	1%		
<u>Tab disp 4 mg</u>	15,985	\$27,462	\$1.7180	C H	1%		
<u>Tab disp 8 mg</u>	6,477	\$13,233	\$2.0430	C H	1%		

SCHEDULE ONE: PHARMACEUTICALS TO BE TENDERED (DRAFT)

Chemical Name

Line Item	Units	Cost	Unit Subsidy	DV Limit	Comments
Oxycodone Hydrochloride					
Cap 5 mg	1,039,973	\$147,156	\$0.1415	+ C H	1%
Cap 10 mg	695,650	\$194,086	\$0.2790	+ C H	1%
Cap 20 mg	372,631	\$182,030	\$0.4885	+ C H	1%
Inj 10 mg per ml, 1 ml	22,764	\$65,560	\$2.8800	C H	1%
Inj 10 mg per ml, 2 ml	21,769	\$125,389	\$5.7600	C H	1%
<u>Oral liq 5 mg per 5 ml</u>	715,606	\$32,059	\$0.0448	C H	1%
Tab controlled-release 5 mg	640,801	\$240,621	\$0.3755	+ C H	1%
Tab controlled-release 10 mg	1,415,423	\$788,391	\$0.5570	+ C H	1%
Tab controlled-release 20 mg	879,265	\$832,224	\$0.9465	+ C H	1%
Tab controlled-release 40 mg	303,822	\$505,712	\$1.6645	+ C H	1%
Tab controlled-release 80 mg	139,168	\$403,796	\$2.9015	+ C H	1%
Paracetamol					
Suppos 125 mg	66,981	\$25,084	\$0.3745	C H	1%
Suppos 250 mg	43,621	\$31,407	\$0.7200	C H	1%
Suppos 500 mg	129,304	\$53,015	\$0.4100	C H	1%
Paraldehyde					
Inj 5 ml	219	\$65,700	\$300.0000	C H	1%
Paroxetine hydrochloride					
Tab 20 mg	13,646,015	\$2,683,716	\$0.1967	C H	1%
Pethidine Hydrochloride					
Inj 50 mg per ml, 1 ml	23,247	\$24,177	\$1.0400	C H	1%
Inj 50 mg per ml, 1.5 ml			\$0.8700	C H	1%
Inj 50 mg per ml, 2 ml	70,243	\$77,267	\$1.1000	C H	1%
Tab 50 mg	278,785	\$83,636	\$0.3000	C	
Tab 100 mg	105,727	\$42,291	\$0.4000	C	
Phenobarbitone					
Tab 15 mg	84,843	\$4,018	\$0.0474	C H	1%
Tab 30 mg	781,463	\$38,432	\$0.0492	C H	1%
Pramipexole Hydrochloride					
Tab 0.125 mg				C H	1% Not currently listed on the Pharmaceutical Schedule. Tender agreement may be subject to a Special Authority restriction
Tab 0.250 mg				C H	1% Not currently listed on the Pharmaceutical Schedule. Tender agreement may be subject to a Special Authority restriction
Tab 1 mg				C H	1% Not currently listed on the Pharmaceutical Schedule. Tender agreement may be subject to a Special Authority restriction

SCHEDULE ONE: PHARMACEUTICALS TO BE TENDERED (DRAFT)

Chemical Name	Units	Cost	Unit Subsidy	DV Limit	Comments
Line Item					
Pramipexole Hydrochloride					
Tab 1.5 mg				C H 1%	Not currently listed on the Pharmaceutical Schedule. Tender agreement may be subject to a Special Authority restriction
Prilocaine Hydrochloride					
<u>Inj. 0.5%, 50 ml</u>				H 1%	
<u>Inj. 2%, 5 ml</u>				H 1%	
Rizatriptan benzoate					
Wafer 10 mg	130,467	\$1,101,141	\$8.4400	+ C H 1%	
Ropinirole Hydrochloride					
<u>Tab 0.25 mg</u>	308,433	\$29,007	\$0.0940	C H 1%	
<u>Tab 1 mg</u>	710,596	\$341,086	\$0.4800	C H 1%	
<u>Tab 2 mg</u>	375,380	\$271,346	\$0.7229	C H 1%	
<u>Tab 5 mg</u>	75,658	\$81,062	\$1.0714	C H 1%	
Sertraline					
Tab 50 mg				C H 1%	Not currently listed on the Pharmaceutical Schedule. Tender agreement may be subject to a Special Authority restriction
Tab 100 mg				C H 1%	Not currently listed on the Pharmaceutical Schedule. Tender agreement may be subject to a Special Authority restriction
Suxamethonium					
<u>Inj 50 mg per ml, 2 ml</u>				H 1%	
Tetrabenazine					
Tab 25 mg	116,287	\$252,301	\$2.1696	C H 1%	
Tolcapone					
Tab 100 mg	116,011	\$149,364	\$1.2875	C H 1%	
Venlafaxine					
Tab immediate-release 12.5 mg				C H 1%	Not currently listed on the Pharmaceutical Schedule. Tender agreement may be subject to a Special Authority restriction
Tab immediate-release 25 mg				C H 1%	Not currently listed on the Pharmaceutical Schedule. Tender agreement may be subject to a Special Authority restriction
Tab immediate-release 37.5 mg				C H 1%	Not currently listed on the Pharmaceutical Schedule. Tender agreement may be subject to a Special Authority restriction
Tab immediate-release 50 mg				C H 1%	Not currently listed on the Pharmaceutical Schedule. Tender agreement may be subject to a Special Authority restriction

SCHEDULE ONE: PHARMACEUTICALS TO BE TENDERED (DRAFT)

Chemical Name

Line Item	Units	Cost	Unit Subsidy	DV Limit	Comments
Venlafaxine					
Tab immediate-release 75 mg				C H 1%	Not currently listed on the Pharmaceutical Schedule. Tender agreement may be subject to a Special Authority restriction
Tab immediate-release 100 mg				C H 1%	Not currently listed on the Pharmaceutical Schedule. Tender agreement may be subject to a Special Authority restriction

Oncology Agents and Immunosuppressants

Amsacrine

Inj 75 mg H PCT 1%

Arsenic trioxide

Inj 10 mg H PCT 1%

Azathioprine

Inj 50 mg 30 \$1,390 \$46.3300 C H 1%

Tab 50 mg 3,637,906 \$909,477 \$0.2500 C H 1%

Bacillus Calmette-Guérin (BCG) Vaccine

Inj containing equal to or greater than 500 million CFU H PCT 1%
 Not currently listed on the Pharmaceutical Schedule. Tender agreement would be for non-vaccine use and may be subject to a Special Authority restriction

Bleomycin sulphate

Inj 15,000 iu H 1%

Busulphan

Tab 2 mg 7,423 \$3,555 \$0.4789 C

Carmustine

Inj 100 mg H 1%

Chlorambucil

Tab 2 mg 85,751 \$76,661 \$0.8940 C H 1%

Cisplatin

Inj 10 mg H PCT 1%
 Not currently listed on the Pharmaceutical Schedule

Inj 50 mg H PCT 1%

Inj 100 mg H PCT 1%

Cladribine

Inj 1 mg per ml, 10 ml H PCT 1%

Inj 2 mg per ml, 5 ml H PCT 1%

Cyclophosphamide

Tab 50 mg 88,044 \$45,272 \$0.5142 C H 1%

Cyclosporin A

Cap 25 mg 1,032,971 \$1,756,051 \$1.7000 C H 1%

SCHEDULE ONE: PHARMACEUTICALS TO BE TENDERED (DRAFT)

Chemical Name	Units	Cost	Unit Subsidy	DV Limit	Comments
Line Item					
Cyclosporin A					
Cap 50 mg	280,201	\$948,985	\$3.3868	C H	1%
Cap 100 mg	488,652	\$3,310,031	\$6.7738	C H	1%
Oral liq 100 mg per ml	16,189	\$122,188	\$7.5476	C H	1%
Cytarabine					
Inj 100 mg			\$16.0000	C H	1%
Inj 500 mg			\$19.0720	C H	1%
Inj 1 g			\$42.6500	C H	1%
Inj 2 g				H	1%
Dacarbazine					
Inj 50 mg				H PCT	1%
Inj 200 mg				H PCT	1%
Dactinomycin (actinomycin D)					
Inj 0.5 mg				H PCT	1%
Daunorubicin					
Inj 20 mg				H PCT	1%
Etoposide					
Cap 50 mg	7,910	\$134,759	\$17.0365	C H	1%
Cap 100 mg	554	\$18,876	\$34.0730	C H	1%
Etoposide Phosphate					
Inj 100 mg (of etoposide base)				H PCT	1%
Exemestane					
Tab 25 mg	134,667	\$785,558	\$5.8333	C H	1%
Fluorouracil Sodium					
<u>Inj 25 mg per ml, 100 ml</u>				H PCT	1%
<u>Inj 50 mg per ml, 10 ml</u>				H PCT	1%
<u>Inj 50 mg per ml, 20 ml</u>				H PCT	1%
<u>Inj 50 mg per ml, 50 ml</u>				H PCT	1%
<u>Inj 50 mg per ml, 100 ml</u>				H PCT	1%
Flutamide					
Tab 250 mg	453,951	\$179,311	\$0.3950	C H	1%
Gemcitabine Hydrochloride					
<u>Inj 200 mg</u>				H PCT	1%
<u>Inj 1 g</u>				H PCT	1%
Imatinib Mesylate					
Tab 100 mg	395,319	\$15,812,760	\$40.0000	+ C H	1%
					Tender agreement may be subject to a Special Authority restriction
Lomustine					
Cap 10 mg				H PCT	1%

SCHEDULE ONE: PHARMACEUTICALS TO BE TENDERED (DRAFT)

Chemical Name	Line Item	Units	Cost	Unit Subsidy	DV Limit	Comments
Lomustine	Cap 40 mg				H PCT 1%	
Melphalan	Inj 50 mg				H PCT 1%	
	Tab 2 mg	14,585	\$18,266	\$1.2524	C H 1%	
Mercaptopurine	Tab 50 mg	212,009	\$399,086	\$1.8824	C H 1%	
Mesna	Tab 400 mg				H PCT 1%	
	Tab 600 mg				H PCT 1%	
	<u>Inj 100 mg per ml, 4 ml</u>				H PCT 1%	
	<u>Inj 100 mg per ml, 10 ml</u>				H PCT 1%	
Methotrexate	Inj 25 mg per ml, 2 ml	6,882	\$63,452	\$9.2200	C H 1%	
	Inj 25 mg per ml, 20 ml	23	\$1,846	\$80.2500	C H 1%	
	Inj 10 mg per ml, 0.75 ml prefilled syringe				C H 1%	Not currently listed on the Pharmaceutical Schedule. Tender agreement may be subject to a Special Authority restriction
	Inj 10 mg per ml, 1 ml prefilled syringe				C H 1%	Not currently listed on the Pharmaceutical Schedule. Tender agreement may be subject to a Special Authority restriction
	Inj 10 mg per ml, 1.5 ml prefilled syringe				C H 1%	Not currently listed on the Pharmaceutical Schedule. Tender agreement may be subject to a Special Authority restriction
	Inj 10 mg per ml, 2 ml prefilled syringe				C H 1%	Not currently listed on the Pharmaceutical Schedule. Tender agreement may be subject to a Special Authority restriction
	Inj 10 mg per ml, 2.5 ml prefilled syringe				C H 1%	Not currently listed on the Pharmaceutical Schedule. Tender agreement may be subject to a Special Authority restriction
Mitomycin C	Inj 2 mg				H PCT 1%	
	Inj 10 mg				H PCT 1%	
Mitozantrone	Inj 2 mg per ml, 5 ml				H PCT 1%	
	Inj 2 mg per ml, 10 ml				H PCT 1%	
Octreotide (somatostatin analogue)	LAR inj 10 mg	226	\$400,585	\$1,772.5000	C H 1%	
	LAR inj 20 mg	953	\$2,247,889	\$2,358.7500	C H 1%	

SCHEDULE ONE: PHARMACEUTICALS TO BE TENDERED (DRAFT)

Chemical Name	Units	Cost	Unit Subsidy	DV Limit	Comments
Line Item					
Octreotide (somatostatin analogue)					
LAR inj 30 mg	744	\$2,195,730	\$2,951.2500	C H 1%	
Pentostatin (deoxycycoformycin)					
Inj 10 mg				H PCT 1%	
Procarbazine Hydrochloride					
Cap 50 mg				H PCT 1%	
Sirolimus					
Oral liq 1 mg per ml	2,839	\$23,081	\$8.1300	C H 1%	
Tab 1 mg	83,240	\$676,741	\$8.1300	C H 1%	
Tab 2 mg	3,572	\$58,081	\$16.2600	C H 1%	
Tacrolimus					
Cap 0.5 mg	135,044	\$288,994	\$2.1400	C H 1%	
Cap 1 mg	1,069,733	\$4,578,457	\$4.2800	C H 1%	
Cap 5 mg	64,144	\$1,372,682	\$21.4000	C H 1%	
Temozolomide					
Cap 5 mg	3,957	\$39,570	\$10.0000	C H 1%	
Cap 20 mg	8,369	\$284,546	\$34.0000	C H 1%	
Cap 100 mg	7,341	\$1,233,288	\$168.0000	C H 1%	
Cap 250 mg	382	\$160,440	\$420.0000	C H 1%	
Teniposide					
Inj 10 mg per ml, 5 ml				H PCT 1%	
Thalidomide					
Cap 50 mg				H PCT 1%	
Thioguanine					
Tab 40 mg	6,434	\$25,005	\$3.8864	C H 1%	
Thiotepa					
Inj 15 mg				H PCT 1%	
Topotecan					
Inj 1 mg				H PCT 1%	Not currently listed on the Pharmaceutical Schedule. Tender agreement may be subject to a Special Authority restriction
Inj 4 mg				H PCT 1%	Not currently listed on the Pharmaceutical Schedule. Tender agreement may be subject to a Special Authority restriction
Tretinoin					
Cap 10 mg				H PCT 1%	
Vincristine Sulphate					
Inj 1 mg per ml, 1 ml				H PCT 1%	
Inj 1 mg per ml, 2 ml				H PCT 1%	

SCHEDULE ONE: PHARMACEUTICALS TO BE TENDERED (DRAFT)

Chemical Name

Line Item	Units	Cost	Unit Subsidy	DV Limit	Comments
Zoledronic Acid					
Inj 4 mg				H 1%	
Inj 5 mg				H 1%	

Respiratory System and Allergies

Beclomethasone Dipropionate

Metered aqueous nasal spray, 50 mcg per dose	12,722,366	\$149,488	\$0.0118	C H 1%
Metered aqueous nasal spray, 100 mcg per dose	47,280,695	\$581,553	\$0.0123	C H 1%

Budesonide

Metered aqueous nasal spray, 50 mcg per dose	5,268,675	\$61,907	\$0.0118	C H 1%
Metered aqueous nasal spray, 100 mcg per dose	30,304,478	\$395,473	\$0.0131	C H 1%

Ipratropium Bromide

<u>Aqueous nasal spray, 0.03%</u>	784,748	\$331,164	\$0.4220	C
<u>Nebuliser soln, 250 mcg per 1 ml</u>	78,380	\$16,852	\$0.2150	C H 1%
<u>Nebuliser soln, 500 mcg per 2 ml</u>	412,284	\$108,225	\$0.2625	C H 1%

Loratadine

<u>Oral liq 1 mg per ml</u>	8,544,371	\$311,870	\$0.0365	C H 1%
<u>Tab 10 mg</u>	14,238,914	\$509,753	\$0.0358	C H 1%

Salbutamol

<u>Oral liq 2 mg per 5 ml</u>	1,019,202	\$15,288	\$0.0150	C H 1%
-------------------------------	-----------	----------	----------	--------

Sensory Organs

Paraffin Liquid with Soft White Paraffin

<u>Eye oint with soft white paraffin</u>	101,341	\$105,105	\$1.0371	C
--	---------	-----------	----------	---

Sodium Cromoglycate

Eye drops 2%	494,850	\$195,466	\$0.3950	C
--------------	---------	-----------	----------	---

Various

Desferrioxamine Mesylate

<u>Inj 500 mg</u>	22,093	\$218,721	\$9.9000	C H 1%
-------------------	--------	-----------	----------	--------

Naloxone Hydrochloride

Inj 400 mcg per ml, 1 ml	11,165	\$73,689	\$6.6000	C H 1%	Min-I-Jet would not be DV Pharmaceutical
--------------------------	--------	----------	----------	--------	--